Precision Medicine

Global Precision Medicine Partnering Deal Trends, Players and Financials Analysis 2014-2019 | PR Newswire | 12/5/2019

Global Precision Medicine Partnering Deal Trends, Players and Financials Analysis 2014-2019 News provided by Research and Markets Dec 05, 2019, 13:30 ET DUBLIN , Dec. 5, 2019 /PRNewswire/ – The “Global Precision Medicine Partnering 2014-2019: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering. The Global Precision Medicine Partnering 2014-2019 report provides comprehensive understanding and unprecedented access to the Precision medicine partnering deals and agreements entered into by the …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

SALT LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine , announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis . The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass …

Follow Precision Medicine:    

Top 8 Predictions That Will Disrupt Healthcare in 2020 | Forbes | 12/4/2019

… gen health data analytics solutions We believe, in the coming decade, cognitive analytic platforms capable of leveraging genomic, clinical, and lifestyle data available to deliver actionable clinical insights will bridge the last mile for precision medicine into clinical practice. We estimate that the precision medicine informatics service market will cross the $5 billion mark by the end of 2020. A precision medicine SaaS-based cognitive insight platform with desired interoperability …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicine s for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

Toward a “head-to-toe” health check from a single blood test | 12/4/2019

… that are able to identify and measure thousands of different circulating proteins from a small blood sample to reveal information about the health of organs across the body. Peter Ganz, MD, hopes to advance precision medicine by partnering to develop a “liquid health check” technology — a single blood test capable of showing current health and future disease risks. Credit: UCSF In a proof-of-concept study published Dec. 2, 2019 …

Big data toolkit to mine the dark genome for precision medicine | Phys Org | 12/4/2019

… functions, and can facilitate the development of precision medicine. Genes are the functional units of heredity, and the understanding of gene function is the major focus of biomedical research, serving as the basis of precision medicine . However, most research efforts have been devoted to only a small part of the genes, neglecting the larger “dark genome.” This impedes our understanding of the underlying mechanisms of complex traits and diseases, which …

Ibex Medical Analytics and the Kahn-Sagol-Maccabi (KSM) Research and Innovation Institute at Maccabi Healthcare Services Roll Out the First-ever AI-powered Diagnostic System for Detecting Breast Cancer in Pathology | PR Newswire | 12/4/2019

… the way in cutting edge medical technology, comprehensive and integrated computerized information systems, cost–effective management and sophisticated monitoring and evaluation tools. The Kahn-Sagol-Maccabi Research and Innovation Institute’s vision is to accelerate precision medicine and lead in big data analytics. We aim to increase the amount and quality of medical research being performed at any given moment in Israel and worldwide and partner with the most advanced AI …

Cognizance Biomarkers Initiates Clinical Trial to Confirm Its Test Can Distinguish Epileptic Seizures from Psychogenic Nonepileptic Seizures | PR Newswire | 12/4/2019

… of Evogen, is a neurology and neuroinflammation-focused diagnostics company focused on achieving leadership in proteomic and genomic-based testing for improved diagnosis and treatment of neurological disorders, offering rapid, accurate and cost-effective precision medicine solutions for optimal patient outcomes. Cognizance Biomarkers’ patented EvoScoreDX biomarker-based blood test has the potential to revolutionize the diagnosis of epilepsy. In clinical trials, EvoScoreDX demonstrated sensitivity of 100% and specificity of 90 …

Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care | PR Newswire | 12/4/2019

… for my patients to more accurately diagnose them and to better individualize their treatments.” About Caris Life Sciences Caris Life Sciences ® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized …

Innovating Your Way Out Of The Resource Curse | Forbes | 12/4/2019

… and Genome Programme, and the cutting-edge Sidra Medicine teaching and research hospital specializing in women’s and children’s health. These projects sit alongside the National AI Strategy that was published recently, with biomedicine and precision medicine one of the pillars of the strategy. To date, over 15,000 Qataris have had their genomes sequenced as part of the Qatar Biobank project, with the ultimate aim to ensure all citizens have their …

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… development of early and more accurate diagnostic tests, as well as tests that can accelerate and improve the rigor of clinical drug development,” Dr. Fillit added. “Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.” The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical Practice Henrik Zetterberg , M.D., University of Gothenburg ($3,197,896), Sweden : Dr. Zetterberg …

Bridging the gap between military prolonged field care monitoring and exploration spaceflight: the compensatory reserve | Nature | 12/4/2019

… should provide early, sensitive, and specific indicators of impending physiological compromise. Because physiological compensation is highly individualized, these technologies must also distinguish between various individual responses to better inform accurate medical decision making (i.e., precision medicine ). Under the PFC directive, new technology for individualized monitoring of a patient’s physiological status is one of the key capability gaps listed by the U.S. Military. 2 Coincidentally, there is a monitoring capability known …

Asia-wide genome mapping project reveals insights into Asian ancestry and genetic diversity | Phys Org | 12/4/2019

… in Asia to date. The study covers 64 different countries and provides what the authors call “the first comprehensive genetic map for Asia” that will guide scientists in studying diseases unique to Asians, improve precision medicine and identify drugs that may carry higher risk of adverse reactions for certain ethnic groups . Despite forming over 40 per cent of the world’s population, Asian people have previously accounted for only six per …

All of Us | Nature | 12/4/2019

DNA-based medicine needs more diversity to avoid harmful bias. One big research project is fixing that. Stephanie Devaney Molecular geneticist Stephanie Devaney is deputy director of the All of Us research program at the National Institutes of Health. She was the staff lead for the White House Precision Medicine initiative. Search for this author in: PDF version When the race to sequence the first human genome was rushing toward …

Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML) | PR Newswire | 12/4/2019

… guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2018 …

Astarte Medical Announces Expansion of Leadership Team with Recognized Industry Veterans to Support its Mission of Improving Preterm Infant Outcomes | Markets Insider | Business Insider | 12/4/2019

YARDLEY, Pa. , Dec. 4, 2019 /PRNewswire/ – Astarte Medical, the only precision medicine company using software and predictive analytics to improve preterm infant outcomes, today announced the addition of three new executives to its leadership team. The company has appointed retired Professor of Pediatrics (Neonatology) at the University of Colorado Denver , Dr. William W. Hay, Jr. , as its Chief Medical Officer. Additionally, Astarte Medical has strengthened its commercialization team, welcoming Steve …

Towards precision security | 12/4/2019

… wants tailor-made security. Personalized customer experience is definitely not a new concept. One industry which has a lot in common with the security industry is going through a big revolution in this direction. Precision medicine ( PM ) is a term describing the customization of the healthcare practices to the individual person. There are multiple benefits to this approach, mainly improving the quality of patient care, enabling cost-effectiveness, and reducing …

Myriads Prequel Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Financial Buzz | 12/4/2019

SALT LAKE CITY, Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine , announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis . The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass index (BMI). The Prequel Prenatal …

Myriad Genetics (NASDAQ:MYGN) Shares Stop Bleeding on Positive Study of Prenatal Genetics Test | 12/4/2019

December 4, 2019 It’s certainly been a white-knuckle ride in 2019 for shareholders of the molecular diagnostics and precision medicine s company Myriad Genetics (NASDAQ: MYGN), with shares doubling and getting halved over a few weeks this summer. A slow climb starting in June from $22 culminated with a 55% explosion on August 1-2 to $48 thanks to news that UnitedHealthcare (NYSE: UNH) was starting to cover a MYGN genetics …

Cancer Research: New clinical trial designs in the era of precision medicine. | 12/4/2019

New clinical trial designs in the era of precision medicine. Mol Oncol. 2019 03;13(3):549-557 Authors: Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J Abstract Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those …

Genomics

Science X Newsletter Tuesday, Dec 3 | 12/4/2019

… or CBC, should be more efficient. Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour … gaining a better understanding of the whales’ lives. Researchers use genomics to discover potential new treatment for parasite disease Using innovative RNA sequencing techniques, researchers at the University of Maryland School of Medicine (UMSOM) Institute …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Biomarkers • Efficacy Biomarkers • Validation Biomarkers • This report also breaks down the revenue forecast for the global biomarkers market by Discipline: • Genomics • Proteomics • Bioinformatics • Other • This report also breaks down the revenue forecast for the global … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Biotech

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Cleveland HeartLab Clinigene International Comprehensive Biomarker Center (formerly Febit) Covance Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… early detection of Alzheimer’s disease and related dementias. To date, funding has been awarded to 10 researchers worldwide, representing academia, biotech and a nonprofit consortium, with investments totaling nearly $10 million focused on developing blood … Fillit added. “Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.” The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical …

Molecular Diagnostics

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening | Globe Newswire | 12/4/2019

SALT LAKE CITY, Dec. 04, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis . The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass …

Food and Drug Administration

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… British Heart Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Piramal Pharma Solutions Announces Collaboration With BerGenBio on the Development of FDA Fast Track Designated Leukemia Treatment | PR Newswire | 12/3/2019

… elderly patients with relapsed Acute Myeloid Leukemia (AML). Bemcentinib was recently designated as a Fast Track drug by the U.S. Food and Drug Administration (FDA), as there are currently no marketed drugs specifically approved for … is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK . The company is listed on the Oslo Stock …

Precision Medicine Market

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Changing Dynamics of the Worldwide Precision Medicine Market Outlook: Ken Research | 12/3/2019

Buy Now The precision medicine is an effective combination of the molecular biology way and systems biology, is a developing method for disease cure and protection. Moreover, the precision medicine is depend on a unique … supervision of the medications. According to the report analysis, ‘ Global Precision Medicine Market (2018-2023)’ states that in the global market of the precision medicine, there are numerous key players which are proficiently functioning more significantly …

Clinical Data

Assistant Professor (Ladder Rank) Chancellor’s Joint Initiative: Biomedical Informatics/Data Sciences | Nature | 12/4/2019

clinical data research network covering over 21 million patients and 10 health systems, and the NIH -funded California Precision Medicine Consortium. Additionally, the DBMI has a central role in clinical and research informatics at the UCSD Health System. Funded with a $75M endowment, the mission of Halicioğlu Data Science Institute ( HDSI ) is to explore the scientific foundations for the new field of data science . These foundations include both the principles …

Christine Swisher | 12/3/2019

… Nathan White, PhD, CEO of HealthLytix. “Her unique expertise in leveraging AI and machine learning to integrate genetics, imaging, and clinical data will be invaluable to helping us expand and advance our portfolio of genetics … MRI physics and computer vision and completed postdoctoral training in precision medicine at Harvard Medical School and Massachusetts General Hospital. About HealthLytix At HealthLytix, we’re using cutting-edge advances in genetics and medical imaging to …

NIH

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… of Allergy and Infectious Diseases (NIAID) [US] National Institute on Aging ( NIA) [US] National Jewish Health [US] Newcastle University [UK] NIH (National Institute of Health) Oslo University Hospital Pharmaceutical Research and Manufacturers of America (PhRMA … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Assistant Professor (Ladder Rank) Chancellor’s Joint Initiative: Biomedical Informatics/Data Sciences | Nature | 12/4/2019

NIH -funded National Centers for Biomedical Computing ( NCBC ), and currently leads several others such as pSCANNER (patient-centered SCAlable National Network for Effectiveness Research, a PCORI -funded clinical data research network covering over 21 million patients and 10 health systems, and the NIH -funded California Precision Medicine Consortium. Additionally, the DBMI has a central role in clinical and research informatics at the UCSD Health System. Funded with a $75M endowment …

National Institutes of Health

Highly sensitive epigenomic technology combats disease | 12/4/2019

… assays in one run. “By comparing normal and diseased epigenomes, useful markers and patterns can be discovered and used for precision medicine based on epigenomic features of an individual patient,” Lu said. This research builds … and Bioengineering, the National Human Genome Research Institute of the National Institutes of Health, and the Virginia Tech Institute for Critical Technology and Applied Science’s Center for Engineered Health …

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… World Health Organization (WHO) To see a report overview please e-mail Sara Peerun on [email protected] Related reports: Global Genomics Market Report 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Clinical Research

[email protected] Puts Patients at the Center, with Live and Archivable Internet Radio Talk Shows Featuring Patients, Advocates and Leading Oncology Researchers | 12/4/2019

… participated in clinical trials. In the talks, important questions are discussed and experiences shared on subjects ranging from immunotherapy and precision medicine to new developments in breast cancer screening. These talks hosted by Priya Menon … UCSF Helen Diller Family Comprehensive Cancer Center combines basic science, clinical research, epidemiology/cancer control and patient care from throughout the University of California, San Francisco system. The UCSF Helen Diller Family Comprehensive Cancer Center …

[email protected] Puts Patients at the Center, with Live and Archivable Internet Radio Talk Shows Featuring Patients, Advocates and Leading Oncology Researchers | Benzinga | 12/4/2019

… participated in clinical trials. In the talks, important questions are discussed and experiences shared on subjects ranging from immunotherapy and precision medicine to new developments in breast cancer screening. These talks hosted by Priya Menon … UCSF Helen Diller Family Comprehensive Cancer Center combines basic science, clinical research, epidemiology/cancer control and patient care from throughout the University of California, San Francisco system. The UCSF Helen Diller Family Comprehensive Cancer Center …

Digital Health

Top 8 Predictions That Will Disrupt Healthcare in 2020 | Forbes | 12/4/2019

… high out-of-pocket spending by patients. Prediction 4: Continued VC funding mega-rounds make 2020 a banner year for Digital Health Unicorns’ IPO exits There are two reasons we expect increased IPO activity in … telehealth by adding more capabilities beyond the home. Prediction 7: Precision medicine-led approaches will pave the way for next-gen health data analytics solutions We believe, in the coming decade, cognitive analytic platforms capable …

All of Us | Nature | 12/4/2019

… All of Us research program at the National Institutes of Health. She was the staff lead for the White House Precision Medicine initiative. Search for this author in: PDF version When the race to sequence … electronic health record system. New apps on smartphones and other digital health technologies such as smart watches collect data from nearly anywhere and directly from a person. These trends all make it easier to store …

Myriad Genetics

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

… Therapeutics Mitsubishi UFJ Capital Mizuho Capital Moffitt Cancer Center Morgan Noble Morgenthaler Ventures Morphic Therapeutics MPM Capital MS Ventures Mylan Myriad Genetics National Agency for Science and Technology National Cancer Institute National Human Genome Research … SBI Investment Scripps Research Institute Sectoral Asset Management Selvita SEngine Precision Medicine Senhwa Biosciences Sequoia China Shanks Lab Sheba Medical Center Shinsei Capital Partners Sierra Oncology SignalRx Pharmaceuticals Silicon Valley Bank Singapore Ministry of Education …

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening Nasdaq:MYGN | Globe Newswire | 11/11/2019

SALT LAKE CITY, Nov. 11, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Ultrasound in Obstetrics and Gynecology . The key finding is that Prequel without a fetal-fraction threshold achieves high accuracy, while maintaining a low test-failure rate of …

CStone Pharmaceuticals

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

… of Medicine Clovis Oncology Cold Spring Harbor Laboratory Columbia University Columbia University Medical Center Cornerstone Parkwalk Advisors CRT Pioneer Fund CStone Pharmaceuticals Cyteir Therapeutics Daiichi Sankyo Dana-Farber Cancer Institute Decheng Capital Delphi Ventures Driehaus … SBI Investment Scripps Research Institute Sectoral Asset Management Selvita SEngine Precision Medicine Senhwa Biosciences Sequoia China Shanks Lab Sheba Medical Center Shinsei Capital Partners Sierra Oncology SignalRx Pharmaceuticals Silicon Valley Bank Singapore Ministry of Education …

Blueprint Medicines’ Avapritinib Grows to Curb Revenue Reliance | Zacks | 10/14/2019

… Free Report ) . The company’s top line mainly comprises collaboration revenues generated from its partnership with Roche ( RHHBY - Free Report ) and CStone Pharmaceuticals for the development and commercialization of its pipeline candidates. Blueprint Medicines’ lead pipeline … The company also plans to initiate a global phase III precision medicine study — COMPASS-2L — to evaluate the safety and efficacy of avapritinib for treating second-line GIST. Other than GIST, Blueprint Medicines is pursuing …

Pfizer

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications | Globe Newswire | 12/4/2019

… Rad’ Pathogen Detection Testing Products Epigenomics AG Receives CE Mark for Liquid Biopsy Test for Liver Cancer Detection Myriad and Pfizer Inks Deal to Commercialize Myriad’s BRACAnalysis CDx as a Companion Diagnostic with Pfizer’s Talazoparib … to Improve Cancer Immunotherapy Biomarker Discovery Thermo Fisher Scientific Opens Precision Medicine Science Center in The United States Myriad Genetics to Acquire Counsyl Thermo Fisher Scientific Inks Deal with Daiichi Sankyo and Takeda Pharmaceuticals to …

Thermo Fisher

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications | Globe Newswire | 12/4/2019

… Biosystems Ink Deal to Market Products for High Throughput Spatial Analysis New Immunoassay for Kratom Alkaloid Mitragynine Screening Introduced by Thermo Fisher Scientific Bio-Techne and NanoString in Collaboration to Develop Integrated Workflow for RNA … to Improve Cancer Immunotherapy Biomarker Discovery Thermo Fisher Scientific Opens Precision Medicine Science Center in The United States Myriad Genetics to Acquire Counsyl Thermo Fisher Scientific Inks Deal with Daiichi Sankyo and Takeda Pharmaceuticals to …

Merck

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

InterVenn Biosciences Releases First-Ever Software for AI-Enabled Mass Spec Analysis | Malvern Daily Record | 12/4/2019

Merck and NASA. To find out more about InterVenn Biosciences and how the company is leveraging artificial intelligence and mass spectrometry to transform medical technology, visit https://intervenn.bio . For all general and media inquiries about InterVenn Biosciences, please contact Andrea Vuturo at [email protected] . About InterVenn Biosciences InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company’s applications include …

Novartis

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Top 8 Predictions That Will Disrupt Healthcare in 2020 | Forbes | 12/4/2019

… by the end of 2020. Alongside leading private insurance companies such as Cigna and CVS, leading gene therapy manufacturers like Novartis, Bluebird Bio, and Spark Therapeutics will continue to explore annuity-based specialized reimbursement programs … telehealth by adding more capabilities beyond the home. Prediction 7: Precision medicine-led approaches will pave the way for next-gen health data analytics solutions We believe, in the coming decade, cognitive analytic platforms capable …

Qiagen

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… plc • Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications | Globe Newswire | 12/4/2019

… NEO Systems by Bruker NanoString Collaborated with National Cancer Institute to Improve Cancer Immunotherapy Biomarker Discovery Thermo Fisher Scientific Opens Precision Medicine Science Center in The United States Myriad Genetics to Acquire Counsyl Thermo Fisher … and Commercialization of Blood-Based Biomarkers for TBI Singulex and QIAGEN Partners for Companion Diagnostics Development Commercial Release of Vectra Polaris Pathology Imaging System by PerkinElmer Illumina Signs Integrated Genomics Solutions Deal with Philips For …

Siemens

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Inc Randox Laboratories Randox Laboratories Roche SABiosciences (now part of QIAGEN) Sandor Proteomic Sanger Institute Sanofi Santaris Pharma Servier Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications | Globe Newswire | 12/4/2019

… Diagnostic Assay to detect 11 PIK3CA Gene Mutations Establishment of APIS Assay Technologies Ltd. for Broadening Biomarker Research in Europe Siemens Releases a Novel Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay for Diabetes Development … to Improve Cancer Immunotherapy Biomarker Discovery Thermo Fisher Scientific Opens Precision Medicine Science Center in The United States Myriad Genetics to Acquire Counsyl Thermo Fisher Scientific Inks Deal with Daiichi Sankyo and Takeda Pharmaceuticals to …

Thermo Fisher Scientific

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications | Globe Newswire | 12/4/2019

… Biosystems Ink Deal to Market Products for High Throughput Spatial Analysis New Immunoassay for Kratom Alkaloid Mitragynine Screening Introduced by Thermo Fisher Scientific Bio-Techne and NanoString in Collaboration to Develop Integrated Workflow for RNA … to Improve Cancer Immunotherapy Biomarker Discovery Thermo Fisher Scientific Opens Precision Medicine Science Center in The United States Myriad Genetics to Acquire Counsyl Thermo Fisher Scientific Inks Deal with Daiichi Sankyo and Takeda Pharmaceuticals to …

Bristol-Myers Squibb

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… World Health Organization (WHO) To see a report overview please e-mail Sara Peerun on [email protected] Related reports: Global Genomics Market Report 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications | Globe Newswire | 12/4/2019

… NEO Systems by Bruker NanoString Collaborated with National Cancer Institute to Improve Cancer Immunotherapy Biomarker Discovery Thermo Fisher Scientific Opens Precision Medicine Science Center in The United States Myriad Genetics to Acquire Counsyl Thermo Fisher … of bioMrieux’s Immunoassay Biomarkers Portfolio by Acquiring Astute Illumina and Bristol-Myers Squibb Collaborate to Develop and Market CDxs for Cancer Drugs Release of Magnetom Sola and BioMatrix Technology by Siemens to Expand Personalized Medicine …

SV Life Sciences

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Globe Newswire | 1/9/2020

Precision Medicine Senhwa Biosciences Sequoia China Shanks Lab Sheba Medical Center Shinsei Capital Partners Sierra Oncology SignalRx Pharmaceuticals Silicon Valley Bank Singapore Ministry of Education Singapore sovereign wealth fund Sloan-Kettering Inst Can Research Sloan-Kettering Institute SMBC Venture Capital Snap Bio Sofinnova Partners SOSV SR One SRI International St George Hospital St. Jude Children’s Research Hospital Stanford University Sungent Bioventure SV Health Investors SV Life Sciences SyntheX Labs Taikang …

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

Precision Medicine Senhwa Biosciences Sequoia China Shanks Lab Sheba Medical Center Shinsei Capital Partners Sierra Oncology SignalRx Pharmaceuticals Silicon Valley Bank Singapore Ministry of Education Singapore sovereign wealth fund Sloan-Kettering Inst Can Research Sloan-Kettering Institute SMBC Venture Capital Snap Bio Sofinnova Partners SOSV SR One SRI International St George Hospital St. Jude Children’s Research Hospital Stanford University Sungent Bioventure SV Health Investors SV Life Sciences SyntheX Labs Taikang …

Goldman Sachs

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard University Helmholtz Zentrum Mnchen Hercules Capital Histalim HuaKong Equity Investment …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard University Helmholtz Zentrum Mnchen Hercules Capital Histalim HuaKong Equity Investment …

Amgen Ventures

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB), A STAR Atlas Venture AUM LifeTech Avecia Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences Benitec Biopharma Biogen Biomics Biotechnologies (a GE Unit) Bioneer BioNTech Biosettia BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB), A STAR Atlas Venture AUM LifeTech Avecia Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences Benitec Biopharma Biogen Biomics Biotechnologies (a GE Unit) Bioneer BioNTech Biosettia BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad …

Lincoln Park Capital Fund

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … of Inhalation Research, Korea Institute of Toxicology Legend Sky Investment Lincoln Park Capital Fund Lonza The University of Texas MD Anderson Cancer Center Mallinckrodt Pharmaceuticals Marina Biotech Massachusetts Institute of Technology Medison Pharma miRagen Therapeutics …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … of Inhalation Research, Korea Institute of Toxicology Legend Sky Investment Lincoln Park Capital Fund Lonza The University of Texas MD Anderson Cancer Center Mallinckrodt Pharmaceuticals Marina Biotech Massachusetts Institute of Technology Medison Pharma miRagen Therapeutics …

JP Morgan

Veeva Systems Inc (VEEV) Q3 2020 Earnings Call Transcript | The Motley Fool | 11/27/2019

… to the operator for questions. Questions and Answers: Operator [Operator Instructions] And our first question comes from Sterling Auty with JP Morgan. Your line is open. Sterling Auty – JP Morgan – Analyst Yes. Thanks. Hi, guys … overall is growing and the number with the move to precision medicine, the number of biotechs is growing, is up significantly from when Veeva started in 2017. So the market is actually for eTMF has …

Artificial Intelligence Stocks to Watch in 2020 | 11/15/2019

… insights. Microsoft has used this technology to develop products across a variety of sectors and industries including human language technologies, precision medicine, assistive robotics, medical imaging readers, genomics and the consumer-facing platform Cortana. Microsoft … platform. Now Amazon is using partnerships with major players like JP Morgan and Berkshire Hathaway to deliver the technology to even more spaces like healthcare. And Amazon Web Services (AWS) is also a major profit …

Broadview Ventures

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB), A STAR Atlas Venture AUM LifeTech Avecia Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences Benitec Biopharma Biogen Biomics Biotechnologies (a GE Unit) Bioneer BioNTech Biosettia BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB), A STAR Atlas Venture AUM LifeTech Avecia Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences Benitec Biopharma Biogen Biomics Biotechnologies (a GE Unit) Bioneer BioNTech Biosettia BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge …

EcoR1 Capital

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … CureDuchenne Dana-Farber Cancer Institute Dharmacon Dicerna Pharmaceuticals Domain Associates EcoR1 Capital Eli Lilly Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma Genesis Pharmaceuticals …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … CureDuchenne Dana-Farber Cancer Institute Dharmacon Dicerna Pharmaceuticals Domain Associates EcoR1 Capital Eli Lilly Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma Genesis Pharmaceuticals …

Oxford Finance

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … Novozymes Oligoengine OliX Pharmaceuticals Omnia Biologics OnCore Biopharma OriGene Technologies Oxford Finance Partner Fund Management PCI Biotech Pfizer Phio Pharmaceuticals (previously known as Rxi Pharmaceuticals) Phyzat Biopharmaceuticals QIAGEN QianHai Fund of Funds Qianhai Shenghui Investment …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … Novozymes Oligoengine OliX Pharmaceuticals Omnia Biologics OnCore Biopharma OriGene Technologies Oxford Finance Partner Fund Management PCI Biotech Pfizer Phio Pharmaceuticals (previously known as Rxi Pharmaceuticals) Phyzat Biopharmaceuticals QIAGEN QianHai Fund of Funds Qianhai Shenghui Investment …

Domain Associates

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … Creative Biogene CureDuchenne Dana-Farber Cancer Institute Dharmacon Dicerna Pharmaceuticals Domain Associates EcoR1 Capital Eli Lilly Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … Creative Biogene CureDuchenne Dana-Farber Cancer Institute Dharmacon Dicerna Pharmaceuticals Domain Associates EcoR1 Capital Eli Lilly Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma …

Atlas Venture

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB), A STAR Atlas Venture AUM LifeTech Avecia Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences Benitec Biopharma Biogen Biomics Biotechnologies (a GE Unit) Bioneer BioNTech Biosettia BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB), A STAR Atlas Venture AUM LifeTech Avecia Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences Benitec Biopharma Biogen Biomics Biotechnologies (a GE Unit) Bioneer BioNTech Biosettia BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge …

MD Anderson Cancer Center

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Malvern Daily Record | 12/4/2019

Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients with relapsed …

Mayo Clinic

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… of QIAGEN) Isogen Life Science Johnson & Johnson (J&J) KU Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Cognizance Biomarkers Initiates Clinical Trial to Confirm Its Test Can Distinguish Epileptic Seizures from Psychogenic Nonepileptic Seizures | PR Newswire | 12/4/2019

… and genomic-based testing for improved diagnosis and treatment of neurological disorders, today announced initiation of a clinical trial with Mayo Clinic that aims to confirm its blood-based protein biomarker test and algorithm accurately … treatment of neurological disorders, offering rapid, accurate and cost-effective precision medicine solutions for optimal patient outcomes. Cognizance Biomarkers’ patented EvoScoreDX biomarker-based blood test has the potential to revolutionize the diagnosis of epilepsy. In …

Massachusetts General Hospital

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… US] Hirosaki University Human Proteome Organisation (HUPO) International Cancer Genome Consortium (ICGC) Les entreprises du médicament (LEEM) [ France ] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Christine Swisher | 12/3/2019

precision medicine at Harvard Medical School and Massachusetts General Hospital. About HealthLytix At HealthLytix, we’re using cutting-edge advances in genetics and medical imaging to revolutionize disease screening and early detection so people can enjoy longer, better lives. Sign …

Memorial Sloan Kettering Cancer Center

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… World Health Organization (WHO) To see a report overview please e-mail Sara Peerun on [email protected] Related reports: Global Genomics Market Report 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Updates From the Labs: Taking Skills From Bench to Bedside | 12/1/2019

… of Marie-Josée and Henry R. Kravis Center for Molecular Oncology and member of Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center in New York. Actionable Targets Solit described the NGS assay … all patients are the beneficiaries of this new approach of precision medicine if tumor types do not have approved matched targeted therapy. For those patients, Solit stated that treatment modalities still include chemotherapy and radiation …

University of Texas MD Anderson Cancer Center

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Malvern Daily Record | 12/4/2019

Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients with relapsed …

The University of Texas MD Anderson Cancer Center

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Malvern Daily Record | 12/4/2019

Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients with relapsed …

Boston University School of Medicine

Science X Newsletter Tuesday, Dec 3 | 12/4/2019

… or CBC, should be more efficient. Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour … In an effort to help curtail this crisis, researchers from Boston University School of Medicine (BUSM) describe an approach to ensure Physician Assistant (PA) students graduating from any PA program in Massachusetts will have the …

American Heart Association awards BU professor | 11/25/2019

American Heart Association awards BU professor November 24, 2019 11:36 pm by Mary Lulloff The Boston University School of Medicine. Doctor and professor of medicine Emelia J. Benjamin was honored by the American Heart Association … who has continually contributed to the Council on Genomic and Precision Medicine, according to an American Association for the Advancement of Science press release . Benjamin serves as assistant provost for faculty development at BUMC and …

Harvard Medical School

Christine Swisher | 12/3/2019

precision medicine at Harvard Medical School and Massachusetts General Hospital. About HealthLytix At HealthLytix, we’re using cutting-edge advances in genetics and medical imaging to revolutionize disease screening and early detection so people can enjoy longer, better lives. Sign …

HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on the Future of Precision Medicine | Globe Newswire | 12/3/2019

… 03, 2019 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at … tenure track faculty position in the Department of Pathology at Harvard Medical School. Both her postdoctoral work and academic research at Harvard focused on cellular and molecular mechanisms driving cancer, with a particular interest in …

Partners HealthCare

Genome | What Is Personalized Medicine? | 12/3/2019

… preventing disease as it is at tailoring treatment once it’s there. Call it what you will — personalized medicine, genomic medicine, precision medicine. It’s an approach that emphasizes the ways in which your disease risks are … Human Genome Project,” says Scott T. Weiss, scientific director at Partners HealthCare Center for Personalized Genetic Medicine at Harvard Medical School. Advances in technology have since accelerated the pace of discovery and lowered the cost …

AMRA Medical Announces Qatar Collaboration, Expanding its Global Patient Data Footprint | PR Newswire | 11/21/2019

… AMRA is a digital health company at the forefront of next generation phenotyping, combining AI and real-world data for precision medicine. The company has developed a new global standard in body composition assessment, the … Cornell Medical College-Qatar , the Institute for Healthcare Improvement and Partners Healthcare, Boston . SOURCE AMRA Medical …

Northwestern Medicine

Percentage of African ancestry affects gene expression | 12/2/2019

… African ancestry in a person’s genome determines the level that certain genes are expressed, called mRNA, according to a new Northwestern Medicine study. The discovery could offer insight into the different risk of diseases as … a monolithic group.” Minoli PereraAssociate professor of pharmacology “To have precision medicine may require understanding ancestry and not just the DNA sequence in these minority populations,” she said. The aim of the study is to …

Health Net

UVM Health Network Integrates Genomics with Routine Clinical Care | HealthIT Analytics | 11/11/2019

Precision Medicine News UVM Health Network Integrates Genomics with Routine Clinical Care The health system has begun a pilot project to offer genomic DNA testing to patients as part of their clinical care. Source: Getty Images By November 11, 2019 - The University of Vermont (UVM) Health Network has announced a pilot program introducing genomic DNA testing to routine clinical care, providing individuals with valuable information to guide their health decisions …

University of Vermont Health Network begins offering Genomic DNA Testing – Company Announcement - FT.com | Financial Times | 11/9/2019

BURLINGTON, Vt ., Nov. 8, 2019 /PRNewswire/ – The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the … research will play a leading role in the advancement of precision medicine,” said Dawn Barry , LunaPBC President and Co-founder. “This effort puts patients first to create a virtuous cycle for research that doesn’t sacrifice …

UnitedHealthcare

Genomind Bolsters Medicare Reimbursement Initiatives, Obtaining Z-Codes for Genomind Professional PGx Express | 11/7/2019

… demonstrated improved patient outcomes and reduced costs. KING OF PRUSSIA, Pa.–(BUSINESS WIRE)– Genomind ®, the leading mental health company bringing precision medicine into mainstream mental health treatment, today announced the assignment of a Z-code … relevant to anxiety and depression, and is currently covered by UnitedHealthcare for certain patients. For both the full and CORE reports, Genomind provides medication-specific results to the clinician team only. In addition to the …

Cigna

Retail makes its case, telehealth and voice tech dominate: 6 takeaways from HLTH19 | Healthcare Dive | 11/6/2019

Cigna Ventures, which recently invested in precision medicine company GNS Healthcare, looks for new tools across the areas of insight and analytics, digital health and retail and all-around care delivery and enablement, for example. “We’re looking for companies that are innovative and looking to solve important problems,” Tom Richards, global strategy and business development leader at Cigna, told Healthcare Dive, noting most companies start with a more focused solution …

From 1792 to 2092: Why the Future of Cigna Is All About Personalization | 10/29/2019

Back to All Stories Krishnan Sridharan has a big job. As Chief Growth Officer for Cigna Global Benefits, he’s responsible for planning out the strategy for the global business of a company that has grown for over 225 years and in an industry buffeted by the winds of disruption. Healthcare is in the midst of a period of unprecedented change. From 3D printing organs and tissues to AI-powered precision …

Aetna

LabCorp (LH) Names Two Leaders for Major Business Wings | Zacks | 10/8/2019

Aetna have helped LabCorp become a contracted laboratory provider for all major national plans.Within Covance Drug Development, the company’s ongoing strategic investments in precision medicine, therapeutic expertise, FSP solutions and biologic drug development capabilities steadily increase its win rate with existing partners and new customers. The acquisition of Chiltern is significantly strengthening LabCorp’s strategic position in clinical development and accelerating revenue plus profit growth within Covance. This apart, the company’s …

LabCorp (LH) Names Two Leaders for Major Business Wings - October 8, 2019 - Zacks.com | 10/8/2019

Aetna have helped LabCorp become a contracted laboratory provider for all major national plans. Within Covance Drug Development, the company’s ongoing strategic investments in precision medicine, therapeutic expertise, FSP solutions and biologic drug development capabilities steadily increase its win rate with existing partners and new customers. The acquisition of Chiltern is significantly strengthening LabCorp’s strategic position in clinical development and accelerating revenue plus profit growth within Covance. This apart, the …

Mark Erlander

Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML) | PR Newswire | 12/4/2019

… that onvansertib will be able to rescue AML patients once they develop resistance to frontline treatment with venetoclax,” said Dr. Mark Erlander , Chief Scientific Officer of Trovagene. “In our current Phase 2 AML trial, we … clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in …

David D. Halbert

Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care | PR Newswire | 12/4/2019

… ALISO VIEJO, Calif. , Dec. 4, Caris Life Sciences ® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, and Ambry Genetics (Ambry), a leading clinical genetic testing company, today announced that … quality information they can use to inform treatment decisions,” said David D. Halbert , Caris Life Sciences Chairman, Chief Executive Officer and Founder. “By partnering with Ambry Genetics to better inform patient care, we are able …

Tracy Warren

Astarte Medical Announces Expansion of Leadership Team with Recognized Industry Veterans to Support its Mission of Improving Preterm Infant Outcomes | Markets Insider | Business Insider | 12/4/2019

YARDLEY, Pa. , Dec. 4, 2019 /PRNewswire/ – Astarte Medical, the only precision medicine company using software and predictive analytics to improve preterm infant outcomes, today announced the addition of three new executives to its leadership team … we prepare to launch our NICUtrition® Suite of solutions,” said Tracy Warren , CEO and Co-Founder, Astarte Medical. Dr. Hay, who brings more than 40 years of clinical neonatology and neonatal research experience, will be …

Michael J. Fox

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… World Health Organization (WHO) To see a report overview please e-mail Sara Peerun on [email protected] Related reports: Global Genomics Market Report 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

NIH, FDA Launch Database for Parkinson’s Disease Precision Medicine | HealthIT Analytics | 11/25/2019

Precision Medicine News NIH, FDA Launch Database for Parkinson’s Disease Precision Medicine NIH, the FDA, and others have launched a data knowledge portal to advance precision medicine for Parkinson’s disease. Source: Getty Images By November … plasma, and DNA samples previously collected through programs like the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the National Institute of Neurological Disorders and Stroke (NINDS) BioFIND Study, and several others. AMP PD also …

Bill Gates

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… 2018 with funding commitments totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation … Fillit added. “Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.” The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical …

Alzheimer’s Drug Discovery Foundation’s Diagnostic | 12/4/2019

… 2018 with funding commitments totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation … Fillit added. «Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.» The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical …

Howard Fillit

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… on their promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,” said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation … Fillit added. “Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.” The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical …

Alzheimer’s Drug Discovery Foundation’s Diagnostic | 12/4/2019

… on their promising research efforts and potential to bring simple and affordable diagnostic tests to physicians and patients,» said Dr. Howard Fillit , Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation … Fillit added. «Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.» The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical …

MacKenzie Bezos

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards | PR Newswire | 12/4/2019

… totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal … Fillit added. “Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.” The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical …

Alzheimer’s Drug Discovery Foundation’s Diagnostic | 12/4/2019

… totaling nearly $50 million over three years from partners, including ADDF Co-Founder Leonard A. Lauder , Bill Gates , Jeff and MacKenzie Bezos , the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal … Fillit added. «Ultimately, these tests will represent the beginning of precision medicine for Alzheimer’s disease and related dementias.» The second round of research recipients include the following: Blood Tests in Development – Moving Closer to Clinical …

Richard Godfrey

Piramal Pharma Solutions Announces Collaboration With BerGenBio on the Development of FDA Fast Track Designated Leukemia Treatment | PR Newswire | 12/3/2019

… as a leading CDMO allow us to customize services according to their needs and deliver solutions that benefit the patients.” Richard Godfrey , Chief Executive Officer of BerGenBio , stated that “Outsourcing of development and manufacturing services … is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK . The company is listed on the Oslo Stock …

Kevin Gorman

Neurocrine Bio takes aim at epilepsy with $50 million acquisiton | 12/3/2019

precision medicine drug discovery to benefit the lives of people with epilepsy and serious neurological disorders,” said Kevin Gorman, chief executive of Neurocrine, in a statement. Advertisement Founded 25 years ago, publicly traded Neurocrine is one of San Diego’s longest-tenured biotechnology firms. It focuses on addressing hard-to-cure neurological, endocrine and psychiatric disorders. The company’s portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis. It also has …

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy | PR Newswire | 12/2/2019

… precision medicine drug discovery to benefit the lives of people with epilepsy and serious neurological disorders,” said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. “The agreement with Xenon strengthens Neurocrine Biosciences’ diverse and growing pipeline and reinforces our long-term commitment of becoming a leading neuroscience-focused biopharmaceutical company.” “With its proven expertise in developing and commercializing treatments for neurological disorders, we believe Neurocrine Biosciences is an ideal …

Michael Hall

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace | 12/3/2019

SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that multiple studies will be presented at the 2019 San Antonio Breast … with pathogenic variants in the ataxia telangiectasia mutated (ATM) gene Michael Hall Poster (P5-03-02) Friday, Dec. 13 5:00-7:00 p.m. EndoPredict ® Prognostic value of EndoPredict and Oncotype Recurrence Score according to patients’ age Ivana Sestak Poster …

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium - GuruFocus.com | 12/3/2019

SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. ( MYGN), a leader in molecular diagnostics and precision medicine, today announced that multiple studies will be presented at the 2019 San Antonio Breast Cancer … with pathogenic variants in the ataxia telangiectasia mutated (ATM) gene Michael Hall Poster (P5-03-02) Friday, Dec. 13 5:00-7:00 p.m. EndoPredict ® Prognostic value of EndoPredict and Oncotype Recurrence Score according to patients’ age Ivana Sestak Poster …